The stock hit an all-time high of Rs 210 today. On the BSE, 0.36 lakh shares have been traded so far, compared with an average daily volume of 0.50 lakh shares over the past two weeks.
The stock had outperformed the market over the past month, rising 29.63% as against the Sensex's 0.88% drop.
The stock had outperformed the market over the three months, rising 137.77% as against the Sensex's 3.15% jump.
On the technical front, the stock's daily RSI (relative strength index) stood at 83.352. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30.
On the daily chart, the stock was trading above its 50-day, 100-day, and 200-day simple moving average (SMA), placed at 80.80, 77.33, and 42.35, respectively. These levels will act as crucial support zones in the near term.
Aptus Pharma is engaged in the business of marketing and distribution of finished pharmaceutical formulations.
The company’s consolidated net profit surged 270% to Rs 2.96 crore on a 37.5% jump in net sales to Rs 24.56 crore in FY26 over FY25.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."